title: Psychiatric care during hepatitis C treatment: the changing role of psychiatrists in the era of direct-acting antivirals.
authors.affiliation: From the Medical Psychiatry Program, University Health Network Centre for Mental Health, and the Toronto Centre for Liver Disease, Toronto Western Hospital, University of Toronto, Toronto.
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Sockalingam
authors.affiliation: From the Medical Psychiatry Program, University Health Network Centre for Mental Health, and the Toronto Centre for Liver Disease, Toronto Western Hospital, University of Toronto, Toronto.
authors.forename: Kathleen
authors.initials: K
authors.lastname: Sheehan
authors.affiliation: From the Medical Psychiatry Program, University Health Network Centre for Mental Health, and the Toronto Centre for Liver Disease, Toronto Western Hospital, University of Toronto, Toronto.
authors.forename: Jordan J
authors.initials: JJ
authors.lastname: Feld
authors.affiliation: From the Medical Psychiatry Program, University Health Network Centre for Mental Health, and the Toronto Centre for Liver Disease, Toronto Western Hospital, University of Toronto, Toronto.
authors.forename: Hemant
authors.initials: H
authors.lastname: Shah
mesh_terms: D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D003299:Cooperative Behavior; D003693:Delirium / Q000139:chemically induced; D003866:Depressive Disorder / Q000139:chemically induced* / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D005544:Forecasting; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D006575:Heterocyclic Compounds, 3-Ring / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D033183:Interdisciplinary Communication; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D010819:Physician's Role / Q000523:psychology*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011392:Proline / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D000069616:Simeprevir; D000069474:Sofosbuvir; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D014542:Uridine Monophosphate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D000998:Antiviral Agents; D006575:Heterocyclic Compounds, 3-Ring; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013449:Sulfonamides; D015283:Citalopram; D008803:Mianserin; D011092:Polyethylene Glycols; D012254:Ribavirin; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; D000069616:Simeprevir; D000078785:Mirtazapine; D014542:Uridine Monophosphate; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a; D000069474:Sofosbuvir